Momenta Pharmaceuticals Announces CFO Transition
January 03 2020 - 8:05AM
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) (“Momenta” or the
“Company”), a biotechnology company focused on discovering and
developing novel biologic therapeutics to treat rare
immune-mediated diseases, today announced that it is consolidating
key financial and business functions under Young Kwon, Ph.D.,
Momenta’s Chief Business Officer. With this consolidation, Dr. Kwon
has been appointed to the position of Chief Financial and Business
Officer effective January 8, 2020. Dr. Kwon will add Momenta’s
finance functions to his existing portfolio of investor relations,
corporate and business development, banking relations, and
commercial.
“Young has demonstrated strong leadership during his 9-year
tenure at Momenta, driving our business development efforts and
strategic vision. His leadership of our banking and investor
relations functions during our transition has resulted in renewed
investor confidence as we have restructured into an innovative
biotech focusing on rare immune-mediated disease,” said Craig
Wheeler, President and Chief Executive Officer. “Under Young’s
leadership, this consolidation of functions will allow us to
continue to work to deliver value to our shareholders.”
Dr. Kwon joined Momenta in 2011 and has served in roles of
increasing responsibility since that time. Prior to Momenta, he was
at Biogen Idec in business and corporate development, where he
completed late-stage clinical licensing transactions and other
deals. Prior to that, he worked at Advanced Technology Ventures, a
venture capital firm, where he identified and invested in
early-stage life science companies. He has a Ph.D. in Biological
Chemistry and Molecular Pharmacology from Harvard University, where
he has co-authored numerous peer-reviewed publications in the area
of neurobiology, and an undergraduate degree from MIT.
Momenta is reaffirming its previously announced guidance for the
full year 2019, which was outlined in its third-quarter 2019
earnings press release.
About MomentaMomenta Pharmaceuticals is a
biotechnology company with a validated innovative scientific
platform focused on discovering and developing novel therapeutics
to treat rare, immune-mediated diseases and advancing its late
stage biosimilar portfolio. The Company is headquartered in
Cambridge, MA.
To receive additional information about Momenta, please visit
the website at www.momentapharma.com, which does not form a
part of this press release.
The Company’s logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade
names, trademarks, or service marks are property of their
respective owners.
Forward-Looking Statements Statements in
this press release regarding management's future expectations,
beliefs, intentions, goals, strategies, plans or prospects, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including but not limited
to statements about our future operating efficiency and guidance
for full year 2019. Forward-looking statements may be
identified by words such as "believe," "continue," “plan to”,
"potential," "will," and other similar words or expressions, or the
negative of these words or similar words or expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors, including the risk of
the unpredictable nature of early stage development efforts for our
product candidates; safety, efficacy or tolerability problems with
our product candidates; unexpected adverse clinical trial results;
and those referred to under the section "Risk Factors" in the
Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2019 filed with the Securities and Exchange
Commission, as well as other documents that may be filed by the
Company from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and
factors, the Company's actual results may differ materially from
any future results, performance or achievements discussed in or
implied by the forward-looking statements contained
herein. The Company is providing the information in this press
release as of this date and assumes no obligations to update the
information included in this press release or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
INVESTOR CONTACT: |
MEDIA CONTACT: |
Patty Eisenhaur |
Karen Sharma |
Momenta Pharmaceuticals |
MacDougall Advisors |
1-617-395-5189 |
1-781-235-3060 |
IR@momentapharma.com |
Momenta@macbiocom.com |
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Sep 2023 to Sep 2024